BACKGROUND: Lifetime risk of heart failure has been estimated to range from 20% to 46% in diverse sex and race groups. However, lifetime risk estimates for the 2 HF phenotypes, HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF), are not known.
H
eart failure (HF) is a major public health problem with increasing prevalence, significant mortality and morbidity burden, and high cost of care. 1, 2 Although the incidence of HF has declined modestly over time, its prevalence continues to increase as a result of the aging population; rising burden of HF risk factors such as diabetes mellitus, obesity, and physical inactivity; and lower myocardial infarction (MI) case-fatality rates. 3, 4 This highlights the need for better strategies for the estimation of HF risk and novel approaches to its prevention.
Lifetime risk estimates have emerged as an important concept in the field of cardiovascular disease epidemiology and prevention and provide a comprehensive assessment of the population-level disease burden while accounting for other competing risks such as mortality. 5 Previous investigations have reported overall HF lifetime risk estimates from 20% to 46%. [6] [7] [8] However, the lifetime risk estimates for the 2 HF phenotypes, HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF), have not been studied. This is particularly important because the 2 HF subtypes differ considerably in demographic distribution, underlying pathophysiological mechanisms, and available preventive and therapeutic options. [9] [10] [11] [12] Furthermore, recent studies have also identified distinct risk factors that may differentially predict risk for HFpEF and HFrEF, highlighting the need for more targeted, subtype-specific approaches to prevention. 1, 13, 14 Better understanding of the lifetime risk estimates for HFpEF and HFrEF would provide insight into the populationlevel burden of the 2 HF subtypes that could have implications for resources allocated to preventive strategies. Accordingly, in this study, we sought to define the lifetime risks of HFrEF and HFpEF at selected ages stratified by race, sex, and history of antecedent MI by pooling data from 2 large prospective cohort studies: the CHS (Cardiovascular Health Study) and MESA (Multiethnic Study of Atherosclerosis).
METHODS

Study Population
The data, analytical methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. We pooled participant-level data from the CHS and MESA study, 2 large prospective cohort studies. The study design, participant characteristics, and HF outcomes for these 2 well-established observational cohort studies have been previously published. 15, 16 CHS is an ongoing, prospective, observational cohort study that includes 5888 community-dwelling older adults recruited from a random sample of Medicare-eligible older adults in 2 phases between 1989 to 1990 and 1992 to 1993 across 4 communities in the United States. 16 MESA is an ongoing, prospective, community-based observational study of 6814 middle-aged to older participants from 6 distinct communities in the United States. We included all participants from the 2 cohorts who were >45 years of age without prevalent HF at baseline. 15 CHS and MESA were approved by appropriate institutional review boards, and informed consent was obtained from all study participants. For the present analysis, deidentified participant information was obtained from each of the 2 cohort studies after the study protocol was approved by the Institutional Review Board at University of Texas Southwestern Medical Center, Dallas, TX, and the coordinating centers for both cohorts.
Measurement of Baseline Covariates
In both cohorts, participants underwent baseline examinations that included both self-reported and measured baseline risk factors, the details of which have previously been reported for each cohort. 15, 16 Age, sex, and race at baseline were self-reported, whereas other clinical risk factors such as blood pressure and body mass index were measured with standard protocols in both cohorts. Other clinical characteristics such as history of diabetes mellitus and coronary artery disease at baseline were self-reported and confirmed by the use of medications at the initial visit. Baseline characteristics reported differently across the 2 cohorts were harmonized into standardized categories for individual-level pooling. The main participant characteristics of interest for the lifetime risk estimation were age (years), sex (men versus women), ethnicity (nonblacks versus blacks), prevalent MI at baseline (yes versus no), and incident MI on follow-up antecedent to HF (yes versus no).
Study Measures: Outcomes of Interest
Primary outcomes of interest in this study were the incidence of overall HF and its subtypes, HFrEF and HFpEF. What Are the Clinical Implications?
• These findings provide insights into the long-term burden of HFpEF and HFrEF across different population subgroups • These findings may help health policy makers in appropriate resource allocation for targeting of HFpEF-and HFrEF-specific preventive strategies in the at-risk population.
used an expert committee of physicians to adjudicate clinical HF outcomes on follow-up. [17] [18] [19] [20] In the MESA cohort, after the baseline examination, participants were followed up every 9 to 12 months via telephone to obtain information about interval hospitalizations and new cardiovascular diagnosis. Self-reported diagnosis was verified and confirmed by review of medical records for all hospitalizations or outpatient diagnoses. For this, medical records were abstracted by trained personnel and transmitted to the coordinating center for independent review and event adjudication by 2 physicians (cardiologists or cardiovascular epidemiologists). Any disagreement between the adjudicators was resolved by the morbidity and mortality classification committee. To establish incident HF, a participant was required to have HF symptoms or signs such as shortness of breath or edema, along with a physician's diagnosis of HF with appropriate medical therapy (probable HF) or an objective feature of the disease such as pulmonary edema on chest x-ray or echocardiographic evidence of left ventricular (LV) systolic or diastolic dysfunction (definite HF). A new HF diagnosis was then classified as either HFpEF (LVEF ≥45%) or HFrEF (LVEF <45%) with the use of available data on LVEF from review of medical records. In the CHS cohort, incident HF events were identified by review of the medical records, Centers for Medicare & Medicaid Services claims data, or participant survey answers at study visits. Events were then confirmed by an expert adjudication panel, which required the following for confirmation: the presence of a physician's diagnosis with symptoms (shortness of breath, orthopnea, fatigue, paroxysmal nocturnal dyspnea) or signs (edema, rales, tachycardia) of HF, supporting radiological findings of HF (eg, pulmonary edema on chest x-ray), or any appropriate medical therapy for HF. These events were then classified as either HFpEF (LVEF ≥45%) or HFrEF (LVEF <45%) with the use of data from cardiac imaging performed within 30 days of the event.
19,20
Statistical Analysis
Lifetime risk was determined with a life-table analysis via the Practical Incidence Estimator macro (SAS Institute Inc, Cary, NC), which allows for variable follow-up duration and combines information on participants at each age attained during ORIGINAL RESEARCH ARTICLE follow-up. 21 This approach is consistent with the previously described methods for estimation of lifetime risk for cardiovascular diseases. 5, 7 Briefly, a modified Kaplan-Meier method was used, with death free of HF used as a competing risk to avoid overestimation of lifetime risk. A participant's lifetime risk with this method is therefore simply the cumulative incidence of developing HF over the individual's subsequent lifetime follow-up, which was set at 90 years of age in this study. Each participant was followed up from the age of entry until the first HF event, death, 90 years of age, or censoring in the primary study cohort. Remaining lifetime risk estimates for HFpEF and HFrEF were calculated for index ages of 45, 55, 65, and 75 years in the overall population and across sex-(men versus women) and race-(blacks versus nonblacks) based subgroups. We also determined the remaining lifetime risks for HFpEF and HFrEF in individuals with versus without antecedent MI. For this, we performed additional subgroup analyses to estimate the lifetime risk for HFpEF and HFrEF in participants with versus without interval MI during follow-up. Individuals with an MI event during follow-up before or concurrent with an incident HF event were classified as having antecedent MI. Individuals without an MI event on follow-up or those with incident MI after HF incidence were classified as without antecedent MI. 8 For each HF subtype outcome, mortality and incidence of the other HF subtype were treated as competing events. Finally, the differential impact of competing-risk adjustment on HFpEF and HFrEF risks was evaluated by estimating lifetime risk with and without adjustment for competing risk of mortality and the other HF subtype. Individuals with HF and missing EF were excluded from the HF subtype analysis.
Several sensitivity analyses were performed to test the robustness of our study findings. First, owing to significant missingness in EF among all HF outcomes, additional sensitivity analysis was performed to determine the impact of HF with missing EF on the observed race-and sex-based differences in HFpEF and HFrEF risk. For this, lifetime risk of HFpEF and HFrEF events at the index age of 45 years was estimated with an extreme case scenario approach, first assuming all HF with missing EF events to be HFpEF events and then assuming all HF with missing EF events to be HFrEF events. Second, a sensitivity analysis was also performed to determine the lifetime risk of HF with missing EF at the index age of 45 years across different race-and sex-based subgroups. Third, a sensitivity analysis was performed with alternative EF cutoffs used to define HFpEF (EF >50%) and HFrEF (EF <40%) to determine whether the race-and sex-based differences in lifetime risk of HFpEF and HFrEF are sensitive to EF cutoffs. Finally, additional subgroup analyses were performed to evaluate the impact of baseline diabetes status on lifetime risk of HFpEF and HFrEF. All statistical analyses were performed with SAS statistical software (version 9.1, SAS Institute).
RESULTS
Overall, 12 417 participants were included in this analysis (44.8% men, 22.2% blacks). Baseline characteristics of the study participants can be found in Table 1 . The age distribution of study participants across the 2 pooled cohorts is shown in Figure I in the online-only Data Supplement. Overall, the MESA cohort included participants with a larger age distribution, with all the younger participants (<65 years of age) in the pooled cohort contributed by MESA. After the index age of 45 years, 2178 incident HF events (726 incident HFpEF and 561 incident HFrEF events, the rest with HF and missing EF) were observed over a median follow-up of 11.6 years.
In sex-stratified analyses, the remaining lifetime risk of overall HF was higher in men than women regardless of the index age (Table 2) . Among the 2 HF subtypes, lifetime risk of HFpEF at the index age of 45 through 90 years was similar in men and women (Figure 1 and Table 2 ). In contrast, for HFrEF, the lifetime risk estimates were up to 1.8-fold higher in men compared with women ( Figure 1 and Table 2 ). The lifetime risks for HFpEF and HFrEF were similar in men, whereas 
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women had substantially higher lifetime risk for HFpEF than HFrEF. The lifetime risk of HFpEF and HFrEF was not substantially lower at higher index ages in men and women (Table 2 ). Similar sex-based differences in lifetime risk of HFpEF and HFrEF were also observed in cohort-specific sensitivity analyses of MESA and CHS participants separately (data not shown).
In race-stratified analyses, the remaining lifetime risk of overall HF was higher in nonblacks than blacks regardless of the index age (Table 3) . For the 2 HF subtypes, the remaining lifetime risk of HFrEF at 45 through 90 years of age was similar in nonblacks versus blacks ( Figure 2 and Table 3 ). In contrast, for HFpEF, the lifetime risk estimates were ≈1.5 fold higher in nonblacks compared with blacks ( Figure 2 and Table 3 ). Blacks had similar lifetime risk of HFpEF and HFrEF, whereas nonblacks had higher risk of HFpEF than HFrEF over the remaining life span. The lifetime risk of HFpEF and HFrEF was similar at higher index ages in both blacks and nonblacks (Table 3) .
The remaining lifetime risk of overall HF was 2.5-fold higher in participants with antecedent MI compared with those without antecedent MI at each index age (Table 4) . For the 2 HF subtypes, the lifetime risks of both HFpEF and HFrEF at the index age of 45 through 90 years were significantly higher (2.5-to 4-fold higher, respectively) in participants with antecedent MI compared with those without antecedent MI ( Figure 3 and Table 4 ). Participants with antecedent MI had a similar lifetime risk of HFpEF and HFrEF, whereas those without antecedent MI had a higher risk of HFpEF than HFrEF (Table 4) . Similar patterns of results were observed across increasing index ages in those with and without antecedent MIs.
The impact of competing risks on lifetime risk for HFpEF and HFrEF was assessed by estimating the cumulative risk of HFpEF and HFrEF in unadjusted models without accounting for the competing risk for death and the other HF subtype. The unadjusted cumulative risk of HFpEF and HFrEF at 45 through 90 years was slightly higher than the adjusted lifetime risk estimates (Table 5 ). Furthermore, competing risk adjustment was associated with similar attenuation in the lifetime risk of both HF subtypes. 
Several sensitivity analyses were performed to test the robustness of our study findings. The impact of HF with missing EF events on the observed lifetime risk estimates for HFpEF and HFrEF was also determined with 2 additional approaches. First, the sex-and race-based differences in lifetime risk estimates of HF with missing EF events at different index ages were calculated and noted to be between that for HFpEF and that for HFrEF (Table I in the online-only Data Supplement). Second, the sex-and race-based differences in lifetime risk of HFpEF and HFrEF in the extreme case scenario (first, assuming all HF with missing EF events as HFpEF in 1 extreme scenario and then as HFrEF) analysis were consistent with that observed in the primary analysis (Table  II in the online-only Data Supplement). In a sensitivity analysis using alternative EF cutoffs for HFrEF (<40%) and HFpEF (>50%), the sex-and race-based differences in lifetime risk of HF subtypes were similar to that observed in the primary analysis (Table III in the onlineonly Data Supplement). Additional sensitivity analyses were performed to evaluate the lifetime risk of HFpEF and HFrEF among study participants with or without prevalent diabetes mellitus at baseline. The remaining lifetime risk of HFpEF at 45 through 90 years of age was similar among those with versus without diabetes mellitus at baseline. In contrast, the remaining lifetime risk for HFrEF at the index age of 45 through 90 years was 1.6-fold higher in those with versus without diabetes mellitus at baseline (Table IV in the online-only Data Supplement).
DISCUSSION
In this participant-level pooled analysis from 2 large prospective cohort studies, we observed that, over the lifetime, compared with women, men have a higher lifetime risk of overall HF and HFrEF with a similar lifetime risk of HFpEF. Second, compared with blacks, nonblacks have a similar lifetime risk of developing HFrEF but a higher risk of HFpEF. Finally, the lifetime risks of HFpEF and HFrEF are similar and substantially higher in those with versus those without antecedent MI. To the best of our knowledge, this is the first study to describe the lifetime risk estimates of the 2 HF subtypes, HFpEF and HFrEF.
The study may have public health implications. HF is a growing public health problem, with increasing morbidity and rising healthcare costs attributed to HF care.
1,2 Among the HF subtypes, the burden of HFpEF is increasing in the community more so than HFrEF, and novel approaches to its prevention are urgently needed. 4, 22, 23 Our study findings provide insights into the lifetime risk of HF subtypes across relevant population subgroups. These data may guide health policy makers and public health investigators to predict the relative population burden of the 2 distinct HF subtypes. They will also help identify the high-risk patient population for HFrEF and HFpEF and allow appropriate diseasespecific resource allocation and targeting of preventive strategies. For example, women and nonblacks may be a higher-risk subgroup for HFpEF than HFrEF and may benefit from more aggressive implementation of HFpEF prevention strategies. To this end, previous studies have demonstrated that aggressive hypertension control may lower the risk of incident HFpEF. 24 Similarly, recent studies have also identified lifestyle risk factors such as obesity and physical inactivity as potentially modifiable targets for HFpEF prevention. 25 Future studies are needed to determine whether intensive lifestyle interventions may lower HFpEF incidence in these higher-risk populations.
Consistent with the previously reported observations of higher short-term risk of HFrEF in men, we observed higher lifetime risk of HFrEF in men than women. 13, 14, 26 This may be related to higher burden and earlier onset of coronary heart disease in men than in women. It is noteworthy that lifetime risk of HFpEF in men was also high and comparable to that in women. This finding contrasts with the prevailing notion that HFpEF is predominantly a disease of women based on observations 
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from cross-sectional studies with a higher proportion of women versus men among hospitalized patients with HFpEF. [27] [28] [29] Findings from the present study highlight the significantly high lifetime risk of HFpEF in men, similar to that observed in women, and argue for increased focus on HFpEF prevention in men. Consistent with our findings, in competing risk-adjusted analysis evaluating the predictors of HFpEF and HFrEF in communitybased cohorts such as PREVEND (Prevention of Renal and Vascular Endstage Disease Intervention Trial) and the Framingham Heart Study, female sex was not associated with increased risk of HFpEF compared with men over the 8-to 10-year follow-up. 14, 26 Among racial/ethnic groups, we observed that the lifetime risk of HFpEF was lower in blacks than nonblacks. In contrast, the lifetime risk of HFrEF was not different between the 2 groups. Previous studies have demonstrated lower lifetime risk of overall HF in blacks compared with nonblacks. 7, 30 The findings from our study suggest that this may be largely related to the lower lifetime risk for HFpEF in blacks versus nonblacks with similar risk of HFrEF in the 2 subgroups. The lower lifetime risk of HFpEF in blacks observed in our study is consistent with lower short-term risk of HFpEF reported in the nonblack participants in other cohorts. 19, 30, 31 The observed lower lifetime risk of HFpEF in blacks may be related to higher competing risk of death among blacks before developing HFpEF. 7 As observed in our study, competing risk attenuates the lifetime risk of HFpEF more than that of HFrEF, largely because HFpEF development tends to occur at an older age than HFrEF. Furthermore, the lower incidence of nonfatal MI and higher incidence of fatal MI in blacks versus nonblacks as observed in recent studies may also contribute to the lower lifetime risk of HF in blacks. 32 It is noteworthy that a previous study from the ARIC (Atherosclerosis Risk in Communities) community surveillance observed that blacks had higher rates of first HF hospitalization than whites and a greater proportion of HFrEF versus HFpEF events. 33 However, in contrast to the findings from our study, these observations were based on cross-sectional assessment of HF hospitalizations rates across different racial groups and do not reflect the cumulative lifetime risk of incident HF (outpatient or inpatient) or account for the competing risk of death or other HF subtype. Furthermore, more than half of participants with a first HF hospitalization event reported a history of an HF diagnosis in ARIC cohort, and thus, the reported HF hospitalizations do not reflect true HF incidence rates. In contrast, the incident HF events in the present study represent the first HF diagnosis in the inpatient or outpatient setting. These differences in risk assessment strategies and outcome definition may explain the observed differences in HF risk.
We also found a substantially higher risk of HFpEF among individuals with antecedent MI. This is consistent with the association between history of ischemic heart disease and higher risk of HFpEF over 8 to 10 years of follow-up that has been reported previously. In the Framingham cohort, history of coronary artery disease was strongly associated with risk of both HFpEF and HFrEF.
14 Similarly, in a recent pooled analysis using data from 4 large cohorts, prior MI was associated with higher risk of both HFpEF and HFrEF. 13 We observed that the risks of HFpEF and HFrEF were comparable among individuals with antecedent MI. Among individuals without an MI, the lifetime risk of HFpEF was higher than that of HFrEF. Taken together, these findings suggest that MI increases the risk of both HFpEF and HFrEF, but more so for HFrEF; therefore, prevention of atherosclerotic disease burden may be a use- The primary strengths of our study include the large sample size, the availability of clinically adjudicated data on HFpEF and HFrEF events in the included study cohorts, the use of similar adjudication criteria for clinical HF, and the use of the same EF cutoff for HFpEF and HFrEF in the 2 study cohorts. Several important limitations of our study are also noteworthy. First, the 2 pooled cohorts had different entry criteria and index ages, which may have affected lifetime risk estimates in the pooled study population. Similarly, the risk factor burden was different across the 2 cohorts, which may have influenced the lifetime risk estimates. Second, EF data were missing in a significant proportion of HF events (≈40%) and contributed to an underestimation of the lifetime risk estimates. However, despite the underestimation of overall lifetime risk burden, it is unlikely that the comparison of lifetime risk across different sex-, race-, and MI history-based subgroups would be affected by the missing EF events, as demonstrated in the extreme case scenario sensitivity analysis (Table II in the online-only Data Supplement). Third, we do not have data on objective biomarkers such as NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels at the time of incident HF diagnosis or use of guideline-recommended HFrEF therapies after HF diagnosis. Future studies using other databases with available medication use data from the index hospitalization are needed to better understand the use of these evidence-based therapies across different groups.
CONCLUSIONS
Findings from our study suggest that the lifetime risks for HFpEF and HFrEF vary by sex, race, and history of antecedent MI. These findings may be informative to understand the population burden of the 2 HF subtypes and to help formulate disease-specific preventive strategies in the at-risk population. can be found at CHS-NHLBI.org. The corresponding author had full access to all data in the study and had final responsibility for the decision to submit for publication. All authors have read and agree to the article as written. 
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